From the Analyst's Couch | Published:

Systemic lupus erythematosus

Nature Reviews Drug Discovery volume 8, pages 103104 (2009) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Lupus Foundation of America (LFA). Introduction to Lupus. LFA web site , (2008).

  2. 2.

    et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58, 15–25 (2008).

  3. 3.

    Genentech. Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus. Genentech web site , (2008).

  4. 4.

    FDA. FDA Warns of Safety Concern Regarding Rituxan in New Patient Population. FDA web site [online], , (2006).

Download references

Author information


  1. James Wentworth, Ph.D., is an Analyst in the Immunology & Inflammation team at Datamonitor Healthcare, 108-110 Finchley Road, London NW3 5JJ, UK.

    • James Wentworth
  2. Clare Davies, M.Eng., is Lead Analyst in the Immunology & Inflammation team at Datamonitor.

    • Clare Davies


  1. Search for James Wentworth in:

  2. Search for Clare Davies in:

Corresponding author

Correspondence to James Wentworth.

Supplementary information

PDF files

  1. 1.

    Supplementary information S1 (table)

    Products with PDUFA dates missed in 2008*

About this article

Publication history



Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing